uniQure N.V. Stock News

uniQure surged over 300% following strong 3-year data from its Huntington's trial, yet remains undervalued due to skepticism over trial size and the use of external controls. AMT-130's apparent efficacy and prior alignment with the FDA on accelerated approval position AMT-130 for commercialization in the near term. Relatively modest volumes are needed to justify uniQure's current valuation, mea...

In one of the most incredible single-day moves this year, biotechnology stock uniQure NASDAQ: QURE surged by 284% on Sept. 24. This came as the firm released fantastic clinical results for its developmental medicine, AMT-130.

LEXINGTON, Mass. and AMSTERDAM, Sept. 29, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of its previously announced underwritten public offering of 6,736,841 ordinary shares at a public offering price of $47.50 per share, which includes 947,368 ordinary s...

LEXINGTON, Mass. and AMSTERDAM, Sept. 25, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its previously announced underwritten public offering of 5,789,473 ordinary shares at a public offering price of $47.50 per share, and, in lieu of ordinary shares t...

UniQure announced groundbreaking results for AMT-130, its gene therapy targeting Huntington's disease, showing a statistically significant 75% reduction in disease progression in a pivotal Phase I/II trial. ((UniQure's Press Release, Sep 24, 2025)) This milestone marks the first therapy to meaningfully slow Huntington's progression and positions UniQure to unlock value across revenue growth, ma...

A ClearPoint Neuro's medical device plays an important role in UniQure's effort to battle Huntington's disease.

uniQure N.V. achieved a 75% statistically significant slowing of Huntington's Disease progression with AMT-130 in a pivotal phase 1/2 study. Plan for a pre-BLA meeting with the FDA in H2 2025, targeting a BLA filing for AMT-130 in Q1 2026 and potential Priority Review Designation if granted. With no approved disease-modifying therapies for HD and a $4.27B market opportunity, AMT-130 could trans...

LEXINGTON, Mass. and AMSTERDAM, Sept. 24, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it has commenced a $200 million underwritten public offering of its ordinary shares and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase its ...